ArriVent BioPharma, Inc. Common Stock (AVBP) — Cash Flow-to-Debt Ratio
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Cash Flow-to-Debt Ratio of -1.65x as of March 2026, meaning its operating cash flow of $-41.89 Million could theoretically repay -2% of its total liabilities ($25.32 Million) in one year. Explore long-term investment intensity of ArriVent BioPharma, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ArriVent BioPharma, Inc. Common Stock Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for ArriVent BioPharma, Inc. Common Stock across 5 annual periods. Also explore AVBP total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ArriVent BioPharma, Inc. Common Stock (2021–2025)
Year-by-year debt coverage analysis for ArriVent BioPharma, Inc. Common Stock. For market capitalisation and broader financial context, see AVBP company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | $-160.59 Million | $25.95 Million | ▼ -52.4% |
| 2024 | -4.06x | $-70.21 Million | $17.29 Million | ▲ +14.2% |
| 2023 | -4.73x | $-55.84 Million | $11.80 Million | ▲ +9.2% |
| 2022 | -5.21x | $-43.63 Million | $8.37 Million | ▲ +24.7% |
| 2021 | -6.92x | $-12.59 Million | $1.82 Million | — |